Answer:
c
Explanation:
in the body the blood vessels always stay in tack and they can never get old.
Answer:
the results are published in a journal where studies are reviewed by other experts in the field.
Explanation:
the results are published in a journal where studies are reviewed by other experts in the field.
Answer: Option 1) Medicaid
Explanation:
Through the value based purchasng initiative enacted by Affordable Care Act, in US Healthcare, decided to expand the services of medicaid.
Medicaid provide government sponsored insurance program to the individuals with low income. Medicaid expansion involves that it wil provide long term health care services and pay all the health benefits for more than 70 million people.
Medicaid expansion become efficient health care program as it covers populations with low income, including young children, pregnant women and physically or mentally disable adults. Peopleadded in this program on different eligibility varies widely among states to meet all the states with minimum federal need.
Hence, the correct option is 1) Medicaid.
Answer:
b) blastic red blood cell (RBC).
Explanation:
In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell <u>(RBC) alloantigens</u> in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology.
